Financing, Pharma

Supernus pharma deals for $90 million private placement financing

Posted on 08 May 2013

Tags: , ,

Supernus Pharmaceuticals pharma deals closing an announced private offering of $90 million financing.

The net proceeds from this pharma deals financing offering were approximately $86.4 million, after deducting discounts to the initial purchasers and estimated offering expenses payable by Supernus.

Contemporaneously with the closing of the offering, Supernus used approximately $19.6 million of the net proceeds to repay in full its borrowings under and terminate its secured credit facility.

Supernus intends to use the remainder of the pharma deals net proceeds to fund the commercialization of its approved and tentatively approved epilepsy drugs, Oxtellar XR and Trokendi XR, to continue development of its pipeline products and for other general corporate purposes.

Daily news stories                                                                           

For further deal information visit Current Agreements (subscription required)


View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter


Print Friendly, PDF & Email

Leave a Reply